Skip to search formSkip to main contentSkip to account menu

10 ML sebelipase alfa 2 MG/ML Injection [Kanuma]

Known as: Sebelipase alfa 2 mg in 1 mL INTRAVENOUS INJECTION, SOLUTION, CONCENTRATE [KANUMA], Kanuma 20 MG per 10 ML Injection, 10 ML Kanuma 2 MG/ML Injection 
National Institutes of Health

Related topics

Related topics

7 relations
Albumin Human, USPInjectionKanumacitric acid monohydrate

Broader (1)

sebelipase alfa Injection [Kanuma]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Mangel an lysosomaler saurer Lipase (LAL-D)
ZusammenfassungHintergrund und klinische DarstellungDer Mangel an lysosomaler saurer Lipase (LAL-D) ist eine autosomal rezessiv… 
2018
2018
Sebelipasa (Kanuma®) : Deficiencia de lipasa ácida liposomal
Review
2016
Review
2016
Sebelipase Alfa: A Review in Lysosomal Acid Lipase Deficiency
Sebelipase alfa (Kanuma®, Kanuma™), the first commercially available recombinant human lysosomal acid lipase (LAL), is approved… 
2015
2015
Adsorptive Removal of Phosphate by Calcined Kanuma Clay from Aqueous Solution
The phosphate removal capacity of Kanuma clay, an inexpensive and abundantly available in Japan, has been investigated. Kanuma… 
1994
1994
Studies on the physical properties of horticultural soils, 2: Characteristics of the soil structure and soil water retentivity of Kanuma-tsuchi [Japan].
1988
1988
PHOSPHATE SORPTION ON THE CLAY FRACTION OF KANUMA PUMICE
The phosphate sorption product on the clay fraction of Kanuma pumice (KP clay) after air-drying was revealed to be a material… 
1988
1988
Effect of humic substances in kanuma pumice on hydrothermal synthesis of ZSM-5 zeolite.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)